about
Zika Virus Infection in Australia Following a Monkey Bite in IndonesiaOutcomes of patients with melioidosis treated with meropenemPlasmodium knowlesi malaria in childrenArtemisinin combination therapy for vivax malariaLung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammationThe anaemia of Plasmodium vivax malariaGenomic analysis of local variation and recent evolution in Plasmodium vivax.Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, IndonesiaElusive Plasmodium Species Complete the Human Malaria Genome SetCommon west African HLA antigens are associated with protection from severe malariaHigh morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomenaSafety profile of L-arginine infusion in moderately severe falciparum malariaA randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokineticsMajor burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance studyDihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, MalaysiaThe Treatment of Plasmodium knowlesi Malaria.The fluid management of adults with severe malariaField evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern IndonesiaTherapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia.Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance.Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting.Ex-vivo changes in amino acid concentrations from blood stored at room temperature or on ice: implications for arginine and taurine measurementsSevere congenital malaria acquired in utero.Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence.Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis.Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia.Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.Nitric oxide production and mononuclear cell nitric oxide synthase activity in malaria-tolerant Papuan adultsLung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia.Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications.Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.Normal spirometry, gas transfer and lung volume values in Papua, Indonesia.Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.Improving case definitions for severe malaria.Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria.Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms.Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
P50
Q22330717-38C8937A-4A8A-40F1-B79F-95F64E380E95Q24567571-D4FE1412-5EE2-4067-B139-0854942423F5Q24601728-0BBFC229-7F5F-4576-BE94-04582A5A1C6FQ24622539-40D143C5-63F3-48DF-A881-634B89C28E26Q24653650-319413FF-7597-4AF0-8272-7FDC4783CD3AQ27026970-3A565DB6-64CE-45FE-B28A-FDCB5AF777F9Q27149930-D2F866F9-0BC6-4846-84DE-6E7F690BA7E4Q27306352-B5187A4F-8F5E-4B6E-9184-04D6F7591497Q28030927-CA987DAB-F41C-4844-A122-0703455EF7C9Q28288693-440DE779-2A64-4A28-9FA9-60BCFF83EE9FQ28391941-ACFDAC79-DBD0-405F-A381-BE17B14C4249Q28472935-88B38B24-6C0D-4625-B8BA-ACC8645D8532Q28534942-8FF8591C-18FC-4992-97F0-81B673674B02Q28537653-0BD8C216-AC12-4A7F-BD27-9B0437F2D4EDQ28550436-5C354BFF-942B-4C00-B918-C3A6815026A5Q30244847-29E22A7F-95AD-40FE-ADEF-384E9BD13764Q30619692-0071EBB2-3B32-416B-8E85-593EE2479E0DQ30733767-69C9C3C2-C2FA-4E20-92A2-FA3A462EF4C8Q30761314-BF81CEDA-93B2-4AB7-9792-7DB1BA336B5DQ30808441-1BD4C2DE-FE70-4269-B2F5-D9F30F311450Q30877630-C20421E8-DCA3-4D5E-B665-E1719683A406Q30888060-2E9F601C-930B-47D8-810D-8FEBFFC35F26Q30920871-0478BE60-D6F8-4080-A7ED-46CA8ECC6731Q30980068-F12800AA-8D0B-4861-8DB5-3050730A123CQ30982557-A6DD8DC6-99EA-47A9-886E-90B007ABB7C2Q31001162-9D76008A-030F-4D3A-92FB-71E575B66B06Q31031139-88EF33DA-6F0E-437A-B2CE-B5F4A7FC8454Q31118886-3DB9BC97-3CEA-4020-8D4F-1B8D2BA6B34CQ31147217-51402F4A-0E28-4CF5-9CBD-EDDAD0464A76Q33226507-499A1A6D-4776-4573-9DA4-1606F926FCCEQ33244196-4DDDAC3B-E635-4506-9025-A0DDDB346445Q33259717-80848326-A3C5-4C7B-A8B0-5B29AC2BD939Q33264369-2A1F4ABA-1F26-497E-9675-58FB69A19A15Q33276757-1B22BFF9-EB76-4CD8-ADA0-7A7EB12A41DCQ33279066-23A67719-131E-4803-9C50-1F9A92183A47Q33294900-6BAFED80-264B-4FC0-A1A4-C5F18458214EQ33298467-A78EC46F-7268-4010-9C84-F3DCD0CED9BDQ33303521-F7154983-C303-450E-83FB-00CE67B920C8Q33304430-05317CAE-D0CE-476E-BD95-40F79AE3AE6EQ33313565-4EBF4C1C-C747-4AC7-B31E-5CE086B2603F
P50
description
Australian global and tropical health researcher ORCID ID = 0000-0002-2192-0506
@en
wetenschapper
@nl
name
Nicholas M Anstey
@ast
Nicholas M Anstey
@en
Nicholas M Anstey
@nl
type
label
Nicholas M Anstey
@ast
Nicholas M Anstey
@en
Nicholas M Anstey
@nl
altLabel
Nicholas Anstey
@en
prefLabel
Nicholas M Anstey
@ast
Nicholas M Anstey
@en
Nicholas M Anstey
@nl
P106
P21
P31
P496
0000-0002-2192-0506